Expression level of tRF-31-PER8YP9LON4VD in serum of breast cancer patients and its effect on cell function
何芳 1莫冬萍 2郑钧予 2严枫 2武昱
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 南京中医药大学附属南京市中西医结合医院检验科，南京 210014
2. 南京医科大学附属肿瘤医院检验科，江苏省肿瘤医院，南京 210009
折叠
摘要
目的 检测tRF-31-PER8YP9LON4VD在乳腺癌患者血清中的表达水平及探讨其对乳腺癌细胞功能的影响。 方法 收集2022年4—8月南京医科大学附属肿瘤医院57例乳腺癌患者、39例乳腺良性肿瘤患者和40名正常体检者的血清，同时整理临床特征资料，通过实时荧光定量PCR（RT-qPCR）检测乳腺癌细胞株及乳腺癌患者血清中的tRF-31-PER8YP9LON4VD的表达水平；运用细胞侵袭实验、迁移实验、CCK-8增殖实验等分析tRF-31-PER8YP9LON4VD对乳腺癌细胞功能的影响。采用受试者工作特征（ROC）曲线分析血清中tRF-31-PER8YP9LON4VD在乳腺癌中的诊断效能。采用卡方检验进行tRF-31-PER8YP9LON4VD与临床特征的相关性分析。 结果 tRF-31-PER8YP9LON4VD在乳腺癌细胞株MDA-MB-231（0.50±0.22比1.00±0.01）、T-47D（0.33±0.02比1.00±0.01）和MCF-7（0.50±0.02比1.00±0.01）的tRF-31-PER8YP9LON4VD表达水平明显低于正常乳腺上皮细胞株（1.00±0.01），差异有统计学意义（P均<0.05）。tRF-31-PER8YP9LON4VD在乳腺癌患者血清中的表达水平（1.35±1.25）低于正常体检者（6.42±3.13）和乳腺良性肿瘤患者（9.57±2.11）血清中的表达水平，差异有统计学意义（P均<0.001）。与对照组比较，过表达tRF-31-PER8YP9LON4VD的T-47D（86.67±12.22比532.00±22.68，P<0.001）和MDA-MB-231（535.33±99.12比1 055.67±24.00，P=0.002）侵袭能力较弱，T-47D（442.67±81.79比1 210.67±115.02，P=0.002）和MDA-MB-231（278.67±108.40比571.33±95.37，P=0.015）迁移能力较弱，T-47D和MDA-MB-231增殖能力较弱，差异有统计学意义（P均<0.05）。血清中tRF-31-PER8YP9LON4VD对乳腺癌诊断效能的曲线下面积0.743（95%CI 0.644~0.842），敏感度和特异度分别为89.50%和53.10%。 结论 tRF-31-PER8YP9LON4VD在乳腺癌患者血清中呈低表达，其可能抑制乳腺癌细胞的增殖、迁移和侵袭能力。 Objective To detect the expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients and to explore its effect on the function of breast cancer cells. Methods The serums of 57 breast cancer patients, 39 breast benign tumor patients and 40 normal physical examination patients in the Affiliated Cancer Hospital of Nanjing Medical University from April to August in 2022 were collected. Real-time quantitative polymerase chain reaction(RT-qPCR) to detect the expression level of tRF-31-PER8YP9LON4VD in breast cancer cell lines and serum of breast cancer patients. Cell invasion assay, migration assay and CCK-8 proliferation assay were used to analyze the effect of tRF-31-PER8YP9LON4VD on breast cancer cell function. The receiver operating characteristic curve (ROC) curve was used to analyze the diagnostic efficacy of tRF-31-PER8YP9LON4VD in serum in breast cancer. The chi-square test was used to analyze the correlation between tRF-31-PER8YP9LON4VD and clinical features. Results The expression levels of tRF-31-PER8YP9LON4VD in breast cancer cell lines MDA-MB-231 (0.50±0.22 vs 1.00±0.01), T-47D (0.33±0.02 vs 1.00±0.01) and MCF-7 (0.50±0.02 vs 1.00±0.01) were significantly lower than those in normal mammary epithelial cell lines (1.00±0.01), and the difference was statistically significant (all P<0.05). The expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients (1.35±1.25) was lower than that in the serum of patients with normal physical examination (6.42±3.13) and patients with benign breast tumors (9.57±2.11), and the difference was statistically significant (bothP<0.001). Compared with the control group, the invasiveness of overexpressing tRF-31-PER8YP9LON4VD T-47D (86.67±12.22vs 532.00±22.68, P<0.001) and MDA-MB-231 (535.33±99.12vs 1 055.67±24.00, P=0.002) was weaker, and that of T-47D (442.67±81.79 vs 1 210.67±115.02, P=0.002) and MDA-MB-231 (278.67±108.40 vs 571.33±95.37, P=0.015) had weaker migration ability, and T-47D and MDA-MB-231 had weaker proliferative ability (all P<0.05). The area under the curve of serum tRF-31-PER8YP9LON4VD for the diagnostic efficacy of breast cancer was 0.743 (95%CI 0.644-0.842), and the sensitivity and specificity were 89.50% and 53.10%, respectively. Conclusion tRF-31-PER8YP9LON4VD is low expressed in the serum of breast cancer patients, and it may inhibit the proliferation, migration and invasion of breast cancer cells.
Abstract
Objective To detect the expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients and to explore its effect on the function of breast cancer cells. Methods The serums of 57 breast cancer patients, 39 breast benign tumor patients and 40 normal physical examination patients in the Affiliated Cancer Hospital of Nanjing Medical University from April to August in 2022 were collected. Real-time quantitative polymerase chain reaction(RT-qPCR) to detect the expression level of tRF-31-PER8YP9LON4VD in breast cancer cell lines and serum of breast cancer patients. Cell invasion assay, migration assay and CCK-8 proliferation assay were used to analyze the effect of tRF-31-PER8YP9LON4VD on breast cancer cell function. The receiver operating characteristic curve (ROC) curve was used to analyze the diagnostic efficacy of tRF-31-PER8YP9LON4VD in serum in breast cancer. The chi-square test was used to analyze the correlation between tRF-31-PER8YP9LON4VD and clinical features. Results The expression levels of tRF-31-PER8YP9LON4VD in breast cancer cell lines MDA-MB-231 (0.50±0.22 vs 1.00±0.01), T-47D (0.33±0.02 vs 1.00±0.01) and MCF-7 (0.50±0.02 vs 1.00±0.01) were significantly lower than those in normal mammary epithelial cell lines (1.00±0.01), and the difference was statistically significant (all P<0.05). The expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients (1.35±1.25) was lower than that in the serum of patients with normal physical examination (6.42±3.13) and patients with benign breast tumors (9.57±2.11), and the difference was statistically significant (bothP<0.001). Compared with the control group, the invasiveness of overexpressing tRF-31-PER8YP9LON4VD T-47D (86.67±12.22vs 532.00±22.68, P<0.001) and MDA-MB-231 (535.33±99.12vs 1 055.67±24.00, P=0.002) was weaker, and that of T-47D (442.67±81.79 vs 1 210.67±115.02, P=0.002) and MDA-MB-231 (278.67±108.40 vs 571.33±95.37, P=0.015) had weaker migration ability, and T-47D and MDA-MB-231 had weaker proliferative ability (all P<0.05). The area under the curve of serum tRF-31-PER8YP9LON4VD for the diagnostic efficacy of breast cancer was 0.743 (95%CI 0.644-0.842), and the sensitivity and specificity were 89.50% and 53.10%, respectively. Conclusion tRF-31-PER8YP9LON4VD is low expressed in the serum of breast cancer patients, and it may inhibit the proliferation, migration and invasion of breast cancer cells.
万方数据